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OBJECTIVE—C57Bl/6 mice develop obesity and mild hypergly-
cemia when fed a high-fat diet (HFD). Although diet-induced
obesity (DIO) is a widely studied model of type 2 diabetes, little
is known about -cell failure in these mice.
RESEARCH DESIGN AND METHODS—DIO mice were sep-
arated in two groups according to body weight gain: low- and
high-HFD responders (LDR and HDR). We examined whether
mild hyperglycemia in HDR mice is due to reduced -cell mass or
function and studied islet metabolism and signaling.
RESULTS—HDR mice were more obese, hyperinsulinemic, in-
sulin resistant, and hyperglycemic and showed a more altered
plasma lipid proﬁle than LDR. LDR mice largely compensated
insulin resistance, whereas HDR showed perturbed glucose
homeostasis. Neither LDR nor HDR mice showed reduced -cell
mass, altered islet glucose metabolism, and triglyceride deposi-
tion. Insulin secretion in response to glucose, KCl, and arginine
was impaired in LDR and almost abolished in HDR islets. Palmitate
partially restored glucose- and KCl-stimulated secretion. The glu-
cose-induced rise in ATP was reduced in both DIO groups, and the
glucose-induced rise in Ca
2 was reduced in HDR islets relatively to
LDR. Glucose-stimulated lipolysis was decreased in LDR and HDR
islets, whereas fat oxidation was increased in HDR islets only. Fatty
acid esteriﬁcation processes were markedly diminished, and free
cholesterol accumulated in HDR islets.
CONCLUSIONS—-Cell failure in HDR mice is not due to
reduced -cell mass and glucose metabolism or steatosis but to
a secretory dysfunction that is possibly due to altered ATP/Ca
2
and lipid signaling, as well as free cholesterol deposition.
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W
hile insulin resistance is a common feature in
most obese subjects, insulin secretion is in-
creased to compensate for its reduced action
and normoglycemia is maintained (1,2). In
obese type 2 diabetes subjects, however, -cell compen-
sation fails due to marked impairment of glucose-stimu-
lated insulin secretion (GSIS), often with reduced -cell
mass (2). The relationship between -cell function and
mass as causative factors in -cell failure and diabetes
progression is debated, with emphasis on the relevance of
“functional -cell mass” rather than total mass (2). In-
creased adiposity leads to elevated circulating free fatty
acids (FFAs) and triglycerides, and in vitro and in vivo
studies have indicated a causative role for dyslipidemia in
insulin resistance (1,3). Although FFAs are necessary for
the ampliﬁcation of GSIS, their excess supply may also
have a role in -cell failure (4), as prolonged elevation of
FFA levels both in vivo and in vitro cause -cell dysfunc-
tion (5,6) and, at least in vitro, apoptosis (7).
At least part of the -cell compensation to insulin
resistance is due to an increase in -cell mass (4). Either
long-term high-fat diet (HFD) (8) or a short-term lipid
infusion (9) can result in increased -cell mass without
augmentation of GSIS, indicating that -cell function and
mass are not necessarily linked. Rodent studies have
indicated that HFD leads to increased -cell mass (8),
which is also observed in normoglycemic obese individu-
als (10). Unclear at present is the dynamics between the
factors driving compensatory increase in -cell mass and
function and those reducing them through the various
stages of type 2 diabetes development, particularly as FFA
may do both. Genetic islet susceptibility may be a critical
determinant of these dynamics, both in humans and ani-
mal models (4,11,12).
Even though studies employing genetically modiﬁed
models (e.g., Zucker Diabetic Fatty rats, db/db mice) have
helped in understanding some of these pathological pro-
cesses (13–16), several of these models are of extreme
nature, with rapid development of pronounced type 2
diabetes. These models, therefore, differ from human
obesity-linked type 2 diabetes, which usually develops
more gradually. In an attempt to gain insight into the basis
of -cell failure in a mild model of diabetes, we recently
developed a new model of type 2 diabetes, the 60%
pancreatectomized obese hyperlipidemic Zucker Fatty rat
(14). In this model, severe -cell dysfunction was found
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steatosis (14). More detailed examination of the pancrea-
tectomized Zucker Fatty rat islets showed marked deple-
tion of insulin stores and altered glycerolipid metabolism
(14). The Zucker Fatty rat, as opposed to the Zucker
Diabetic Fatty rat, however, does not have genetic predis-
position to diabetes, as it maintains normoglycemia de-
spite severe obesity-related insulin resistance (4). The
diet-induced obese (DIO) C57BL/6 mouse gradually devel-
ops hyperglycemia (17). This suggests that DIO islets are
unable to fully compensate for the obesity-related insulin
resistance, as occurs in human type 2 diabetes.
In the present study, we investigated -cell dysfunction
in DIO mice stratiﬁed into two groups according to the
effect of HFD on body weight: the low responders to HFD
(LDR) were less obese, developed intermediate severity of
insulin resistance, and had only mild impairment in glyce-
mia. The high responders to HFD (HDR) were more obese,
insulin resistant, and hyperinsulinemic and were clearly
hyperglycemic. Thus, the LDR and HDR groups allowed
for analysis and comparison of islet -cell mass and function
in response to different levels of insulin resistance with
corresponding very mild perturbation of glucose homeosta-
sis and overt but mild hyperglycemia, respectively. When
extended to obese humans, these two groups correspond to
the pre-diabetes and early diabetes situations.
RESEARCH DESIGN AND METHODS
Animals and diets. Five-week-old male C57BL/6 mice on a pure genetic
background were purchased from Charles River Laboratories (St-Constant,
QC, Canada). We veriﬁed by RT-PCR analysis that this mouse strain does not
harbor a mutation in the nicotinamide nucleotide transhydrogenase gene
found in the C57BL/6J strain (18) (data not shown). They were housed 3–4 per
cage on a 12-h light/dark cycle at 21°C with free access to water and standard
diet (Teklad Global 18% protein rodent diet; Harlan Teklad, Madison, WI, 15%
fat by energy). One week after arrival, mice were fed with either the standard
or HFD (Bio-Ser Diet #F3282, Frenchtown, NJ, 60% fat by energy) for 8 weeks.
Body weight and energy intake were measured weekly. For the energy-intake
measurement, the mice were placed in individual cages. Fed blood glucose
was determined by a portable glucometer (Accu-check Advantage, Roche,
Indianapolis, IN). All procedures were approved by the Institutional Commit-
tee for the Protection of Animals at the Centre Hospitalier de l’Universite ´d e
Montre ´al.
Plasma parameters. Blood was collected between 8:00 and 10:00 A.M.i nf e d
mice. Plasma insulin and proinsulin were measured by radioimmunoassay
(Linco Research, St. Charles, MO) and by ELISA (proinsulin mouse kit, Alpco
Diagnostics, Salem, NH), respectively. Plasma nonesteriﬁed fatty acids
(NEFA) were assessed using the NEFA C kit (Wako Chemical, Osaka, Japan).
Plasma triglyceride was determined with the GPO Trinder kit (Sigma Aldrich,
Saint Louis, MS), and cholesterol was determined with the Amplex red assay
kit (Molecular Probes, Eugene, OR).
Glucose homeostasis, insulin action, and secretion in vivo. Two-hour
hyperinsulinemic euglycemic clamp (HIEC) studies were performed in 2-h–
fasted, anesthetized normal diet, LDR, and HDR mice after 8 weeks on the
experimental diets (19). An intravenous glucose tolerance test (IVGTT) (0.5
g/kg) was conducted in 16-h overnight fasted mice (20). An oral glucose
tolerance test (OGTT) (1 g/kg) was also made in 6-h–fasted mice (20). Blood
glucose was measured using a portable meter, and plasma insulin was
measured using the UltraSensitive mouse Insulin ELISA Kit (Alpco
Diagnostics).
-Cell proliferation and mass. These parameters were measured as de-
scribed (21).
Islet isolation and culture. Islets were isolated as described (22) and kept
in culture at 3 mmol/l glucose for2hi nRPMI medium supplemented with 10%
FBS (complete RPMI) at 37°C, for recovery (23).
Insulin secretion ex vivo. For static incubations, batches of 10 islets each
were distributed in 12-well plates and preincubated for 45 min at 37°C in
Krebs-Ringer bicarbonate containing 10 mmol/l HEPES (pH 7.4) (KRBH), 0.5%
defatted BSA (d-BSA), and 3 mmol/l glucose. They were then incubated for 1 h
in KRBH/0.5% d-BSA at 3, 8, and 16 mmol/l glucose or with 35 mmol/l KCl, in
the presence or absence of 0.25 mmol/l palmitate. After 1 h, media were kept
for insulin measurements by radioimmunoassay. Islet insulin and proinsulin
contents were measured following acid–ethanol (0.2 mmol/l HCl in 75%
ethanol) extraction by radioimmunoassay and ELISA, respectively. For peri-
fusion experiments, batches of 120 cultured islets each were placed in
perifusion chambers at 37°C and perifused at a ﬂow rate of 1 ml/min for 30 min
in KRBH/0.5% d-BSA at 3 mmol/l glucose before stimulation with 16 mmol/l
glucose for 60 min and then with 10 mmol/l arginine for 10 min. Islets were
then perifused at 3 mmol/l glucose for 30 min.
Intracellular calcium. Ca
2 was measured using a modiﬁed version of a
procedure previously described (24). Dispersed-islet cells from 350–500
freshly isolated islets were plated on 42 mm coverslip and incubated at 37°C
overnight in complete RPMI at 11 mmol/l glucose. Cells loaded with Fluo-4 AM
calcium indicator were perifused with KRBH/1% d-BSA, 2.5 mmol/l probeni-
cid, 0.2 mmol/l sulﬁnpyrazone, 0.1 mmol/l IBMX, and 3 or 16 mmol/l glucose
or 3 mmol/l glucose  35 mmol/l KCl. Computational analysis was done using
measurements every 3 s. An average of 25 cells per coverslip was analyzed.
Intracellular ATP content. Batches of 50 islets cultured and preincubated
as described for insulin secretion experiments were incubated for 15 min in
KRBH/0.07% d-BSA at 3 or 16 mmol/l glucose. At the end of the incubation,
ATP was extracted from islets and assayed as described (22).
Islet triglyceride, cholesterol, and protein contents. Triglyceride, cho-
lesterol, and protein contents were measured in batches of 100, 40, and 20
freshly isolated islets, respectively (23,25).
Lipid metabolism. For lipolysis, 60 islets per determination were used (23).
Fatty acid oxidation and esteriﬁcation into cholesterol ester were measured in
batches of 50 islets (14). NEFA content and fatty acid esteriﬁcation into
triglyceride in 50 islets were determined as described (26).
Glucose metabolism. Islet glucose usage and oxidation were measured as
described (22).
Quantitative RT-PCR. See supplemental Research Design and Methods in
the online appendix, which is available at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-1452/DC1.
Statistical analysis. Data are expressed as means  SE. Statistical signiﬁ-
cance was calculated by one-way or two-way ANOVA with Bonferroni, Tukey,
or Dunnett post hoc testing as indicated. A P value of 0.05 was considered
signiﬁcant.
RESULTS
Metabolic characteristics of LDR and HDR mice. For
mechanistic analyses, pooling mice with markedly differ-
ent characteristics (for example, little weight gain, no
insulin resistance, and normoglycemia with animals with
high weight gain, insulin resistance, and hyperglycemia),
as has been done in the vast majority of studies so far, can
be misleading. We reasoned that this caveat can be dealt
with by stratifying mice in two groups (LDR and HDR, as
described below) that correspond on one hand to lower
weight gain and mild perturbation in glucose homeostasis
and on the other hand to higher weight gain and overt but
mild hyperglycemia. On the basis of the heterogeneous
weight response to diet (12 g range for DIO mice housed
by group of 3–4 per cage or individually) (Fig. 1A), DIO
mice were segregated into two groups after 7.5 weeks on
HFD: LDR mice, representing 40% of the DIO mice and
weighing 33–38.9 g (lower 6 g range) with an average fed
glycemia of 8.6  0.1 mmol/l, and HDR mice, representing
52% of the DIO mice and weighing 39–45 g (higher 6 g
range) with an average glycemia of 9.4  0.1 mmol/l (Fig.
1B). DIO outlier mice weighing 33g (4% of total DIO
mice) and 45g (4%) were excluded from this study
(Fig. 1A). The control group fed with the standard diet
(normal diet) had an average weight of 28.3  0.2 g and a
glycemia of 7.5  0.1 mmol/l (Fig. 1B). Difference in body
weight in DIO mice was already present after 1 week
under HFD and steadily increased during the 8 weeks of
the study (Fig. 1C). The considerably larger weight of HDR
mice can be accounted, at least in part, to an increased
energy intake (106.8  1.4 versus 98.3  1.4 kcal/week in
LDR mice, Fig. 1D, inset). Table 1 shows that over 8 weeks
HFD-fed LDR and HDR mice, respectively, gained 2–3 and
3–4 times more weight compared to normal diet mice. LDR
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1B). The 2-h fasting blood glucose of LDR mice was not
signiﬁcantly increased (Fig. 2A). In contrast, the HDR group
showed a more prominent hyperglycemia than LDR mice.
Blood glucose in HDR mice was increased in awake fed mice
(9.4  0.1 vs. 7.5  0.1 mmol/l in normal diet mice, Fig. 1B)
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FIG. 1. Body weight (BW), energy intake, and glycemia of C57Bl/6 mice fed normal diet (ND) or HFD for 8 weeks. DIO mice were classiﬁed after
7.5 weeks on HFD as LDR and HDR following body weight determinations. A: Distribution plots of body weight at 7.5 weeks of ND or HFD mice
housed 3–4 per cage (ND, LDR, and HDR) or individually (NDi and DIOi). Encircled symbol corresponds to DIO mice excluded from the study.
B: Fed glycemia and body weight of ND, LDR, and HDR mice after 7.5 weeks of dietary treatment. (C) Weight and (D) energy intake curves of
ND, LDR, and HDR mice during 8 weeks of ND or HFD. D, inset: Mean of energy intake per week per group. A: Means  SE of 52 mice for ND,
LDR, and HDR, of 13 and 33 mice for NDi and DIOi, respectively. B and C: Means  SE of 136, 117, and 148 mice for the ND, LDR, and HDR groups,
respectively. D: Means  SE of 13, 14, and 17 mice for the ND, LDR, and HDR groups, respectively. ND versus LDR or HDR, **P < 0.01, ***P <
0.001; LDR versus HDR, §P < 0.05, §§P < 0.01, §§§P < 0.001; one-way (B) or two-way ANOVA (C and D), Bonferroni post hoc test.
TABLE 1
Metabolic parameters of C57Bl/6 mice fed with normal diet or HFD for 8 weeks
Fed Fasted
Normal diet LDR HDR Normal diet LDR HDR
Weight gain (g) 8.5  0.2 (62) 15.5  0.2*** (60) 20.4  0.2***,§§§ (72) 5.5  1.0 (5) 16.9  0.6*** (5) 21.0  0.3***,§§ (5)
Insulin (pmol/l) 252  24 (59) 266  20 (58) 658  54***,§§§ (67) 133  87 (5) 338  84 (5) 503  40* (5)
ProIns (pmol/l) 18.5  2.3 (8) 23.7  1.9 (9) 31.8  4.0* (9) ND ND ND
ProIns/Ins (%) 7.8  1.3 (8) 9.4  1.4 (9) 5.5  0.9§ (9) ND ND ND
FFA (mmol/l) 0.60  0.04 (33) 0.55  0.03 (33) 0.58  0.03 (38) 0.77  0.06 (5) 1.12  0.06 (5) 1.58  0.30* (5)
TG (mmol/l) 0.41  0.02 (33) 0.32  0.01*** (34) 0.33  0.01*** (38) 0.36  0.04 (5) 0.40  0.04 (5) 0.39  0.03 (5)
TC (mmol/l) 1.50  0.07 (8) 1.90  0.14 (8) 2.58  0.21***,§ (8) ND ND ND
Data are means  SE of n animals as indicated in parentheses. Plasma triglyceride (TG), FFAs, TC, proinsulin (ProIns), and insulin (Ins) were
determined in anesthetized overnight fasted and/or fed male mice on a high-fat diet (LDR and HDR) or normal diet for 8 weeks. Delta body
weight represents the weight gain of mice since the introduction of diets (normal diet or HFD) at 6 weeks of age. LDR or HDR versus normal
diet: *P  0.05, **P  0.01, ***P  0.001; HDR versus LDR: §P  0.05, §§P  0.01, §§§P  0.001. One-way ANOVA–Bonferroni multiple
comparison test. ND, not determined.
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mmol/l in normal diet mice, Fig. 2A). Glucose levels in
6-h–fasted HDR mice versus normal diet mice (11.6  0.5 vs.
7.4  0.3 mmol/l) were elevated, and the LDR group showed
intermediate values (9.8  0.4 mmol/l) (supplementary Fig.
1A and C, available in an online appendix). Glycemia in
overnight 16-h–fasted HDR mice with anesthesia was slightly
elevated, without reaching statistical signiﬁcance (8.3  0.3
vs. 7.0  0.4 mmol/l, Fig. 2E). Glucose values at time 60 min
during an IVGTT (Fig. 2E) and time 120 min during an OGTT
(supplementary Fig. 1A and D) remained markedly elevated
in HDR, in contrast to the LDR mice. Fasting and fed
insulinemia were 3–4-fold higher in the HDR compared to
normal diet mice, whereas in LDR mice, fed insulinemia was
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FIG. 2. DIO mice are insulin-resistant, are glucose-intolerant, and have defective ﬁrst-phase GSIS. A and B: HIEC in 2-h–fasted anesthetized mice.
A: Arterial glucose levels at time 0 of the clamp; B: glucose levels during the clamp. The dashed line corresponds to the clamped glucose value
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1  min
1
glucose infused per pmol/l insulin. E–I: IVGTT. Plasma glucose (E) and insulin (F) were measured at times 0, 3, 5, 15, 30, 45, and 60 min in
response to a glucose challenge (i.v.; 0.5 g/kg) in 16-h overnight fasted anesthetized mice; (G) AUC of the 0–60 min glycemic responses; (H)
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***P < 0.001; LDR versus HDR: §P < 0.05, §§P < 0.01, §§§P < 0.001; one-way (A, C, D, and G–I) or two-way ANOVA (B, E, and F), with Bonferroni
post hoc test.
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(not statistically signiﬁcant) (Table 1). Fed proinsulinemia
was higher in HDR mice in comparison to normal diet, and
the proinsulin-to-insulin ratio was unchanged in LDR and
HDR mice versus controls. Of the measured lipid parameters,
when compared to normal diet mice, fed plasma cholesterol
was signiﬁcantly increased by 70% in HDR mice, fasting
plasma FFAs were twofold higher in HDR mice, and fed
plasma triglyceride was 30% decreased in both DIO groups
(Table 1).
LDR and HDR mice are insulin-resistant, are glucose-
intolerant, and have a decreased ﬁrst-phase insulin
secretion in response to glucose in vivo. A HIEC was
made in 2-h–fasted normal diet and DIO mice (Fig. 2A–D).
Both the glucose infusion rate (Fig. 2C) required to
maintain glycemia at 7.2 mmol/l (Fig. 2B) and the insulin
sensitivity index (Fig. 2D) were decreased by 50% and
80% in LDR and HDR mice, respectively, indicating that
HDR mice are more insulin resistant than LDR mice. To
measure GSIS in vivo, overnight-fasted DIO and normal
diet mice were subjected to an IVGTT (Fig. 2E–I). Glucose
clearance was reduced in HDR mice (Fig. 2E), indicating a
decreased glucose tolerance as shown by a twofold in-
crease in the area under the curve (AUC) for glycemia
(Fig. 2G). LDR mice tended to be glucose intolerant but
without reaching statistical signiﬁcance (Fig. 2E and G). A
similar observation was made using the OGTT (supple-
mentary Fig. 1A and B). Calculation of the AUC for
insulinemia during the ﬁrst 15 min of the IVGTT, subtract-
ing basal values, indicated that ﬁrst-phase GSIS is reduced
by 66 and 76% in the LDR and HDR groups, respectively
(Fig. 2F and H). However, the AUC for the second-phase
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(Fig. 2F and I).
Impaired insulin secretion in isolated islets from
LDR and HDR mice. We next examined GSIS in the
presence or absence of exogenous FFA in isolated islets.
In normal diet mice, glucose from 3 to 16 mmol/l increased
insulin secretion by 2.6-fold (Fig. 3A). The glucose effect in
both DIO groups was reduced and was almost completely
blunted in HDR mice (Fig. 3A and D). LDR and HDR mice
also showed defective KCl-induced insulin secretion
(KSIS), with the reduction being more pronounced in the
HDR group (Fig. 3C). Exogenous palmitate enhanced GSIS
in the three groups (Fig. 3B) and partially restored GSIS,
as evaluated by the difference between high and low
glucose values (Fig. 3D), as well as KSIS (Fig. 3C) in both
DIO groups. First-phase GSIS was reduced by 47 and 65%
in LDR and HDR perifused islets, respectively (Fig. 3E and
F). HDR mice also showed a ﬁvefold decrease in second-
phase GSIS (Fig. 3G) and in secretion in response to
arginine (Fig. 3H).
Lack of decreased pancreatic -cell mass and islet
insulin stores in DIO islets. HDR mice showed a 1.7-
and 2-fold increase in -cell mass (Fig. 4A) and prolifera-
tion (Fig. 4B), respectively. There was a trend for -cell
mass and proliferation to be increased in the LDR group.
Islet protein contents were increased by 24 and 44% in
LDR and HDR mice, respectively (Fig. C). Total insulin
content per islet was similar in all groups (Fig. 4D);
however, islet content corrected per protein content de-
creased by 20 and 24% in LDR and HDR islets, respectively
(Fig. 4E). The islet proinsulin content per protein was
similar in all groups (Fig. 4F).
Islet glucose metabolism is unchanged in DIO mice.
Previous work in type 2 diabetes rodent models has
suggested a role for altered glucose metabolism in -cell
dysfunction (27,28). Figure 4 indicates that impaired GSIS
in LDR and HDR mice cannot be ascribed to altered
glucose metabolism, because glucose usage (Fig. 4G) and
oxidation (Fig. 4H) were unchanged.
Decreased glucose-stimulated ATP content in DIO
islets and altered Ca
2 signaling in HDR islet cells
versus LDR. Normal diet mice showed a 40% increase in
intracellular ATP content in response to high glucose,
whereas both DIO groups displayed a reduced response
(Fig. 4I). The rise in Ca
2 in response to glucose was
markedly larger in LDR versus normal diet islet cells (Fig.
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ation, which likely reﬂects a compensation phenomenon.
Altered lipid partitioning, reduced glycerolipid/fatty
acid cycling, and free cholesterol deposition in HDR
islets. Islet steatosis was proposed to contribute to -cell
failure (29). However, there was no accumulation of
triglyceride in DIO islets (Fig. 5A). Work from our group
(13,14,22,23) and other groups (30–32) documented a role
of -cell lipolysis and glycerolipid/FFA cycling in insulin
secretion. Lipolysis, evaluated by glycerol release, was
increased twofold by elevated glucose in normal diet islets
(Fig. 5B), and this increase was abolished in DIO islets.
Fatty acid partitioning (fatty acid oxidation and esteriﬁca-
tion) was studied in DIO islets since it provides lipid
signals for secretion (33). Fatty acid oxidation was similar
in both normal diet and LDR islets (Fig. 5C). However,
fatty acid oxidation was increased by 60% in HDR islets.
HDR islets had a 70% higher level of NEFA (an index of
long-chain acyl-CoA content) at 3 mmol/l glucose (Fig.
5D), consistent with the elevated fatty acid oxidation at
low glucose (Fig. 5C). At 16 mmol/l glucose, intracellular
NEFA remained not signiﬁcantly different in all groups
(Fig. 5D). Glucose-stimulated palmitate esteriﬁcation into
triglyceride was reduced by 25% in LDR and HDR islets
(Fig. 5E). An altered lipid esteriﬁcation process in DIO
islets was also evident from the observed reduction in
palmitate esteriﬁcation into cholesterol esters in islets
from both DIO groups (Fig. 5F). This was associated with
a 90 and 60% increase in free cholesterol in HDR versus
normal diet and LDR islets, respectively (Fig. 5G).
Expression of key transcriptional factors, exocytotic
proteins, and enzymes of glucose and lipid metabo-
lism. A panel of mRNA levels was measured to gain insight
into the basis of -cell (de)compensation. Only the mRNA
levels of insulin-2, UCP-2 (uncoupling protein-2), SCD-1
(stearoyl-CoA desaturase-1), ACC-2 (acetyl-CoA carbox-
ylase-2), and ATGL (adipose triglyceride lipase) signiﬁ-
cantly changed in DIO islets (supplementary Figure 2A–D,
available in an online appendix). Insulin-2 mRNA was
increased in both DIO groups, reaching signiﬁcance only
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sion of UCP-2 in the -cell is thought to play a role in
reducing reactive oxygen species production, but the role
of UCP-2 in mitochondrial uncoupling or changes in GSIS
is debated (34,35). UCP-2 mRNA level was increased by
40% in both LDR and HDR islets (supplementary Fig.
2C). A 56% increase in ATGL expression, an enzyme
involved in triglyceride hydrolysis, was detected in HDR
islets (supplementary Fig. 2C), which may reﬂect a com-
pensation phenomenon. In accordance with the increased
FFA oxidation in HDR islets (Fig. 5C) and the decreased
fatty acid esteriﬁcation in triglyceride in DIO islets (Fig.
5E), ACC-2 mRNA was decreased by 45% in HDR islets and
SCD-1 mRNA was reduced in DIO islets (supplementary
Fig. 2D). Thus, SCD-1 is involved in the desaturation of
FFA and is important for fatty acid esteriﬁcation (36),
whereas ACC-2 negatively regulates FFA oxidation via the
production of malonyl-CoA (37).
DISCUSSION
According to body weight response to HFD, we stratiﬁed
C57Bl/6 DIO mice in two groups. HDR mice are markedly
obese, hyperinsulinemic, insulin resistant, and glucose
intolerant and show an altered plasma lipid proﬁle in
association with overt but mild hyperglycemia (Table 2).
LDR mice have an “intermediate” phenotype and show
relatively successful compensation since they are barely
glucose intolerant and only very slightly hyperglycemic.
Thus, deﬁning these two groups allows the study of the
basis of -cell compensation and failure in two groups of
obese mice with the same genetic background and under
identical experimental conditions. The HDR group and its
comparison with LDR and normal diet mice also allows
insight into the causal factors of -cell failure to sustain
the increased demand of insulin in the face of elevated
insulin resistance. Importantly, study of HDR and LDR
mice may distinguish the alterations in the -cell that are
related to coping with the HFD load and obesity situation
from those that may cause -cell maladaptation to the
rising insulin resistance with resulting dysfunction and
mild hyperglycemia (the equivalent of pre-diabetes and
early diabetes phases in humans).
What is the basis of the -cell failure to insufﬁciently
compensate for the higher insulin resistance in HDR mice?
The results allow the exclusion of several factors (Table
2): decreased -cell glucose metabolism, islet steatosis,
reduced -cell mass and proliferation, and depletion of
insulin stores, because the latter was not signiﬁcantly
decreased per islet and reduced by only 30% if expressed
per islet protein in a context where pancreatic -cell mass
increased twofold. However, it cannot be discounted that
failure to promote even greater than twofold compensa-
tory increase in -cell mass, in part, contributed to -cell
failure in the HDR group. Signiﬁcant -cell “dedifferentia-
tion” is also unlikely to be involved in -cell failure of HDR
mice because they were markedly hyperinsulinemic, the
islet mRNA expression of a large number of genes related
to the phenotype of a well differentiated -cell (PDX-1,
MAF-A, Nkx6.1, Glut2, GK, PC, preproinsulin; supplemen-
tary Fig. 2A) was unchanged, and islet glucose oxidation
and usage remained unaltered.
The results point to a role of alterations in the classical
ATP/Ca
2 signaling and lipid ampliﬁcation pathways as
well as free cholesterol deposition, in the failure of the
HDR -cells to compensate for the marked insulin resis-
tance (Fig. 6). Thus, LDR islets displayed an ampliﬁed
Ca
2 response to glucose that was not apparent in the
HDR group, together with reduced rise in ATP content at
high glucose, with the latter, however, also being reduced
in LDR islets. The reason for the enhanced Ca
2 response
in the LDR group that should favor compensating insulin
secretion remains to be determined. Furthermore, LDR
and HDR mice showed altered lipid metabolism and
signaling that may explain reduced glucose-, KCl- and
arginine-induced insulin secretion. Thus, exogenous
palmitate partially restored GSIS and KSIS in islets of both
DIO groups. Importantly, the differences that were found
between the compensating pre-diabetic LDR and decom-
pensating (here deﬁned as insufﬁcient compensation)
HDR groups were enhanced fat oxidation and elevated
intracellular NEFA at basal glucose in HDR islets, in
association with an increased free cholesterol content, as
well as a more pronounced reduction of fatty acid esteri-
ﬁcation into cholesterol esters and SCD-1 expression
(Table 2). Our previous work indicated that both the
balance of fat oxidation versus esteriﬁcation, -cell lipol-
ysis and GL/FFA cycling play a role in GSIS (13,14). As
TABLE 2
Summary of the metabolic and islet -cell parameters obtained in
C57Bl/6 male mice fed a high-fat diet for 8 weeks
LDR HDR
Metabolic parameters
Weight gain 11 1
Insulin resistance 11 1
Insulinemia (1) 11
Proinsulinemia/insulinemia %%
OGTT glucose tolerance (2) 2
ivGTT glucose tolerance (2) 2
ivGTT/1st-phase GSIS 22 2
ivGTT/2nd-phase GSIS %%
Fasting FFA (1) 1
Fed total cholesterol (1) 1
Fed glycemia 11 1
2-h–fasted glycemia (1) 1
6-h–fasted glycemia 11 1
16-h–fasted glycemia % (1)
ivGTT, 1 h glucose %1
OGTT, 2 h glucose (1) 1
Islet -cell parameters
-Cell mass (1) 1
-Cell proliferation (1) 1
Protein content/islet 11 1
Insulin content/islet %%
Proinsulin content/islet protein %%
Glucose-induced insulin secretion 22 2
KCl-induced insulin secretion 22
Glucose usage/oxidation %%
TG content %%
Free cholesterol content %1
Glucose-stimulated lipolysis 22
Glucose effect on NEFA content (2) 2
Glucose effect on FA esterif. in TG 22
FA esteriﬁcation in CE 22 2
FA oxidation %1
Glucose-induced ATP 22
Glucose-induced Ca
2 1%
KCl-induced Ca
2 %%
Horizontal arrow, unchanged versus normal diet–fed animals; arrows
in parentheses indicate a clear trend that did not reach statistical
signiﬁcance. FA, fatty acid; TG, triglyceride.
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lipolysis and fatty acid esteriﬁcation should reduce the
production of lipid signaling molecules such as diacylglyc-
erol (33), which has been linked to the activation of
C-kinase enzymes (38) and the exocytotic protein
Munc13-1 (39), whereas enhanced fat oxidation should
simultaneously cause their removal. Increased fatty acid
oxidation should also reduce fatty acid-CoA availability for
cholesterol ester formation (a protective mechanism
against the toxic effects of excess cholesterol) (40) leading
to free cholesterol accumulation.
Alteration in -cell cholesterol metabolism has emerged
as a factor contributing to -cell dysfunction as evidenced
in a number of in vitro and in vivo studies (25,41,42).
Interestingly, total plasma cholesterol and islet free cho-
lesterol deposition occurred only in the HDR group, illus-
trating the interest of stratiﬁcation of DIO groups.
Cholesterol is abundant in lipid rafts that are implicated in
exocytosis (43), and it can be hypothesized that such
modiﬁcation may contribute to the observed reduction in
insulin secretion in response to all classes of secreta-
gogues. Consistent with this view, Collins et al. (44)
observed reduced -cell exocytosis elicited by short depo-
larization in DIO mice.
Comparison of in vitro and in vivo insulin secretion of
DIO mice indicated that the secretory defect is more
prominent in vitro. The nature of the factors allowing
compensatory increased (but not sufﬁcient) insulin secre-
tion with hyperinsulinemia in vivo remains to be known
and may include FFA as suggested by our in vitro work,
enhanced incretin signaling, reduced levels of counter-
regulatory hormones, and neural pathways (45).
In conclusion, HDR mice fail to fully compensate for the
prominent insulin resistance that exacerbates the demand
for insulin to maintain euglycemia. HDR islets have a
defect in -cell secretory function in response to glucose
and nonfuel stimuli that is possibly caused by 1) a lack of
compensatory increase in ATP/Ca
2 signaling; 2) free
cholesterol accumulation; and 3) impaired lipid signaling
due to a metabolic shift with altered lipid partitioning and
glycerolipid/FFA cycling. We propose that all three factors
contribute to the inappropriate capacity to maintain sufﬁ-
cient secretion in the face of insulin resistance. Additional
work is required to deﬁne in further details the biochem-
ical basis of -cell failure in HDR DIO mice.
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intracellular Ca
2 and a decrease in fatty acid oxidation that allows
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GL/FA cycling is an “on” signal for insulin secretion that contributes to
the ampliﬁcation arm of GSIS. Enhanced fat oxidation is an “off” signal
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fatty acid esteriﬁcation processes and lipolysis are simultaneously
decreased in association with enhanced FFA oxidation. The increase in
fatty acid oxidation, in parallel to depleting LSM, reduces fatty acid-
CoA availability for cholesterol ester (CE) synthesis, contributing
with elevated blood cholesterol to free cholesterol accumulation and
-cell dysfunction with reduced secretion. Besides the ampliﬁcation
arm of GSIS, the classical triggering ATP/Ca
2 pathway is also affected
in HDR versus LDR mice due to reduced glucose-stimulated ATP
production and a lack of compensatory increase in the rise in Ca
2
promoted by high glucose. GPR40 activation by FFA may contribute to
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